Printed from https://ideas.repec.org/s/spr/eujhec.html
Content
December 2023, Volume 24, Issue 9
- 1411-1420 EQ-5D-5L Portuguese population norms
by Pedro L. Ferreira & Luís N. Pereira & Patrícia Antunes & Lara N. Ferreira - 1421-1428 Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study
by Aino Vesikansa & Olli Halminen & Juha Mehtälä & Iiris Hörhammer & Teija Mikkola & Tero Ylisaukko-oja & Miika Linna - 1429-1440 Public preferences for policies promoting a healthy diet: a discrete choice experiment
by C. M. Dieteren & I. Bonfrer & W. B. F. Brouwer & J. Exel - 1441-1454 A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
by Ali Tafazzoli & Odette S. Reifsnider & Leana Bellanca & Jack Ishak & Marc Carrasco & Pal Rakonczai & Matthew Stargardter & Stephan Linden - 1455-1472 Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
by S. W. Quist & A. J. Postma & K. J. Myrén & L. A. Jong & M. J. Postma - 1473-1504 Prescription opioids and economic hardship in France
by Ilaria Natali & Mathias Dewatripont & Victor Ginsburgh & Michel Goldman & Patrick Legros - 1505-1515 Identifying factors associated with high use of acute care in Canada: a population-based retrospective study
by Mengmeng Zhang & Jinhui Ma & Feng Xie & Lehana Thabane - 1517-1530 Population norms in France with EQ-5D-5L: health states, value indexes, and VAS
by Laurène Gautier & Jessica Azzi & Grèce Saba & Geneviève Bonnelye & Gérard Pouvourville - 1531-1543 The social value of gambling: surplus estimates by gambling types for France
by Maxence Miéra & Sophie Massin & Vincent Eroukmanoff - 1545-1559 Cost and cost-effectiveness of four different SARS-CoV-2 active surveillance strategies: evidence from a randomised control trial in Germany
by Hoa Thi Nguyen & Claudia M. Denkinger & Stephan Brenner & Lisa Koeppel & Lucia Brugnara & Robin Burk & Michael Knop & Till Bärnighausen & Andreas Deckert & Manuela De Allegri - 1561-1573 Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data
by Alisa Stöber & Pavo Marijic & Christoph Kurz & Larissa Schwarzkopf & Florian Kirsch & Anja Schramm & Reiner Leidl - 1575-1586 Driving time drives the hospital choice: choice models for pelvic organ prolapse surgery in Italy
by Amerigo Ferrari & Chiara Seghieri & Andrea Giannini & Paolo Mannella & Tommaso Simoncini & Milena Vainieri
November 2023, Volume 24, Issue 8
- 1249-1252 Modeling European health systems: a theoretical exercise
by L. Garattini & Marco Badinella Martini - 1253-1270 To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study
by Ângela Jornada Ben & Johanna M. Dongen & Aureliano Paolo Finch & Mohamed El Alili & Judith E. Bosmans - 1271-1283 The effect of hepatitis C—associated premature deaths on labour productivity losses in Spain: a ten-year analysis
by L. M. Peña-Longobardo & J. Oliva-Moreno & C. Fernández-Rodriguez - 1285-1296 Developing an Australian utility value set for the Early Childhood Oral Health Impact Scale-4D (ECOHIS-4D) using a discrete choice experiment
by Ruvini M. Hettiarachchi & Peter Arrow & Sameera Senanayake & Hannah Carter & David Brain & Richard Norman & Utsana Tonmukayawul & Lisa Jamieson & Sanjeewa Kularatna - 1297-1307 Assessment of health-related quality of life in individuals with depressive symptoms: validity and responsiveness of the EQ-5D-3L and the SF-6D
by Maike Stolz & Christian Albus & Manfred E. Beutel & Hans-Christian Deter & Kurt Fritzsche & Christoph Herrmann-Lingen & Matthias Michal & Katja Petrowski & Joram Ronel & Jobst-Hendrik Schultz & Wolfgang Söllner & Cora Weber & Martina Zwaan & Christian Krauth - 1309-1319 Out-of-pocket costs sustained in the last 12 months by cancer patients: an Italian survey-based study on individual expenses between 2017 and 2018
by Roberto Lillini & Francesco De Lorenzo & Paolo Baili & Elisabetta Iannelli & Laura M. Del Campo & Dina Pero & Gianfranca Traclò & Alessandro Sproviero & Milena Sant & Francesco Perrone - 1321-1341 Social costs of obesity in the Czech Republic
by Petra Landovská & Martina Karbanová - 1343-1355 Cost–benefit analysis of the CoCare intervention to improve medical care in long-term care nursing homes: an analysis based on claims data
by Boris A. Brühmann & Klaus Kaier & Rieka Warth & Erik Farin-Glattacker - 1357-1371 Excess costs of multiple sclerosis: a register-based study in Sweden
by Chantelle Murley & Petter Tinghög & Fitsum Sebsibe Teni & Alejandra Machado & Kristina Alexanderson & Jan Hillert & Korinna Karampampa & Emilie Friberg - 1373-1382 Significant healthcare burden and life cost of spinal muscular atrophy: real-world data
by Sophelia H. S. Chan & Carlos K. H. Wong & Tingting Wu & Wilfred Wong & Michael K. L. Yu & Ivan C. H. Au & Godfrey C. F. Chan - 1383-1397 Insurance coverage, long-term care utilization, and health outcomes
by Masaki Takahashi - 1399-1410 EQ-5D and SF-6D health utility scores in patients with spinal and bulbar muscular atrophy
by Richard Huan Xu & Ming Lu & Shuyang Zhang & Dong Dong
September 2023, Volume 24, Issue 7
- 1019-1021 Competition and collaboration in health care: reconciling the irreconcilable? Lessons from The Netherlands
by Marco Varkevisser & Frédérique Franken & Stéphanie Geest & Erik Schut - 1023-1031 Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries
by Olina Efthymiadou - 1033-1045 The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease
by Zuzana Špacírová & Stephen Kaptoge & Leticia García-Mochón & Miguel Rodríguez Barranco & María José Sánchez Pérez & Nicola P. Bondonno & Anne Tjønneland & Elisabete Weiderpass & Sara Grioni & Jaime Espín & Carlotta Sacerdote & Catarina Schiborn & Giovanna Masala & Sandra M. Colorado-Yohar & Lois Kim & Karel G. M. Moons & Gunnar Engström & Matthias B. Schulze & Léa Bresson & Concepción Moreno-Iribas & David Epstein - 1047-1060 Estimating healthcare expenditures after becoming divorced or widowed using propensity score matching
by Iris Meulman & Bette Loef & Niek Stadhouders & Tron Anders Moger & Albert Wong & Johan J. Polder & Ellen Uiters - 1061-1072 Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy
by India Flint & Jasmina Medjedovic & Ewa Drogon O’Flaherty & Elena Alvarez-Baron & Karthinathan Thangavelu & Natasa Savic & Aurelie Meunier & Louise Longworth - 1073-1083 Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries
by Przemysław Holko & Paweł Kawalec & Magdalena Sajak-Szczerba & Luisa Avedano & Małgorzata Mossakowska - 1085-1100 Do not PIMP my nursing home ride! The impact of Potentially Inappropriate Medications Prescribing on residents’ emergency care use
by Thomas Rapp & Jonathan Sicsic & Neda Tavassoli & Yves Rolland - 1101-1120 The effects of an increase in the retirement age on health care costs: evidence from administrative data
by Johannes Geyer & Mara Barschkett & Peter Haan & Anna Hammerschmid - 1121-1139 The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
by Ingrid A. Cox & Barbara Graaff & Hasnat Ahmed & Julie Campbell & Petr Otahal & Tamera J. Corte & Yuben Moodley & Nicole Goh & Peter Hopkins & Sacha Macansh & E. Haydn Walters & Andrew J. Palmer - 1141-1150 Can drones save lives and money? An economic evaluation of airborne delivery of automated external defibrillators
by Johann W. A. Röper & Katharina Fischer & Mina Carolina Baumgarten & Karl Christian Thies & Klaus Hahnenkamp & Steffen Fleßa - 1151-1216 The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review
by Michela Meregaglia & Elena Nicod & Michael Drummond - 1217-1233 What if 0 is not equal to 0? Inter-personal health utilities anchoring using the largest health gains
by Michał Jakubczyk - 1235-1237 “COVID-19 and income inequality in OECD countries:” A methodological comment
by Oded Stark - 1239-1241 COVID-19 and income inequality in OECD countries: a methodological comment—a reply
by John Wildman - 1243-1244 Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
by Afschin Gandjour - 1245-1248 Does health technology assessment compromise access to pharmaceuticals?
by Melanie Büssgen & Tom Stargardt
August 2023, Volume 24, Issue 6
- 853-865 Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy
by Lars Børty & Rasmus F. Brøndum & Heidi S. Christensen & Charles Vesteghem & Marianne Severinsen & Søren P. Johnsen & Lars H. Ehlers & Ursula Falkmer & Laurids Ø. Poulsen & Martin Bøgsted - 867-875 Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
by Manon Belhassen & Olivier Hanon & Philippe Gabriel Steg & Isabelle Mahé & Mélanie Née & Flore Jacoud & Faustine Dalon & François-Emery Cotté & Dominique Guitard-Dehoux & Claire Marant-Micallef & Eric Van Ganse & Nicolas Danchin - 877-884 Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study
by Tonya Moen Hansen & Knut Stavem & Kim Rand - 885-893 Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients
by Chen-Wei Pan & Jun-Yi He & Yan-Bo Zhu & Chun-Hua Zhao & Nan Luo & Pei Wang - 895-907 The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
by Adie Viljoen & Barrie Chubb & Samuel J. P. Malkin & Sasha Berry & Barnaby Hunt & Stephen C. Bain - 909-922 Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries
by Xiao Li & Joke Bilcke & Alike W. van der Velden & Robin Bruyndonckx & Samuel Coenen & Emily Bongard & Muirrean de Paor & Slawomir Chlabicz & Maciek Godycki-Cwirko & Nick Francis & Rune Aabenhus & Heiner C. Bucher & Annelies Colliers & An De Sutter & Ana Garcia-Sangenis & Dominik Glinz & Nicolay J. Harbin & Katarzyna Kosiek & Morten Lindbæk & Christos Lionis & Carl Llor & Réka Mikó-Pauer & Ruta Radzeviciene Jurgute & Bohumil Seifert & Pär-Daniel Sundvall & Pia Touboul Lundgren & Nikolaos Tsakountakis & Theo J. Verheij & Herman Goossens & Christopher C. Butler & Philippe Beutels - 923-937 Do mobile hospital teams in residential aged care facilities increase health care efficiency: an evaluation of French residential care policy
by Anne Penneau - 939-950 Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand
by Suzi Claflin & Julie A. Campbell & Richard Norman & Deborah F. Mason & Tomas Kalincik & Steve Simpson-Yap & Helmut Butzkueven & William M. Carroll & Andrew J. Palmer & C. Leigh Blizzard & Ingrid van der Mei & Glen J. Henson & Bruce V. Taylor - 951-965 The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?
by Ângela Jornada Ben & Johanna M. Dongen & Mohamed El Alili & Martijn W. Heymans & Jos W. R. Twisk & Janet L. MacNeil-Vroomen & Maartje Wit & Susan E. M. Dijk & Teddy Oosterhuis & Judith E. Bosmans - 967-986 Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks
by Meg Perry-Duxbury & Sebastian Himmler & Job Exel & Werner Brouwer - 987-998 The application of discrete choice experiments eliciting young peoples’ preferences for healthcare: a systematic literature review
by Galina Williams & Irina Kinchin - 999-1017 Does competition improve hospital performance: a DEA based evaluation from the Netherlands
by Peter Dohmen & Martin Ineveld & Aniek Markus & Liana Hagen & Joris Klundert
July 2023, Volume 24, Issue 5
- 673-678 Does diagnostic testing always decrease antibiotics prescriptions?
by F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas - 679-699 The ‘welcomed lockdown’ hypothesis? Mental wellbeing and mobility restrictions
by Joan Costa-Font & Martin Knapp & Cristina Vilaplana-Prieto - 701-715 Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
by Hamraz Mokri & Ingelin Kvamme & Linda Vries & Matthijs Versteegh & Pieter Baal - 717-733 Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach
by Jui-fen Rachel Lu & Ying Isabel Chen & Karen Eggleston & Chih-Hung Chen & Brian Chen - 735-748 Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic
by Yi Wang & Nantasit Luangasanatip & Wirichada Pan–ngum & Wanrudee Isaranuwatchai & Juthamas Prawjaeng & Sompob Saralamba & Christopher Painter & Jamaica Roanne Briones & Yot Teerawattananon - 749-768 Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19
by Gabriela-Mihaela Mureșan & Viorela-Ligia Văidean & Codruța Mare & Monica Violeta Achim - 769-781 Obesity and metabolic state are associated with increased healthcare resource and medication use and costs: a Finnish population-based study
by Aino Vesikansa & Juha Mehtälä & Katja Mutanen & Annamari Lundqvist & Tiina Laatikainen & Tero Ylisaukko-oja & Tero Saukkonen & Kirsi H. Pietiläinen - 783-784 Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al
by Martin Connock & Xavier Armoiry - 785-802 An econometric approach to aggregating multiple cardiovascular outcomes in German hospitals
by Angela Meggiolaro & Carl Rudolf Blankart & Tom Stargardt & Jonas Schreyögg - 803-816 Dividend policy issues in the European pharmaceutical industry: new empirical evidence
by Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg - 817-830 “The reputation premium”: does hospital ranking improvement lead to a higher healthcare spending?
by Jinyang Chen & Chaoqun Wang - 831-852 Estimating the willingness-to-pay to avoid the consequences of foodborne illnesses: a discrete choice experiment
by Kathleen Manipis & Brendan Mulhern & Philip Haywood & Rosalie Viney & Stephen Goodall
June 2023, Volume 24, Issue 4
- 485-487 Tenders for generics and biosimilars: a challenging purchasing policy
by Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas - 489-497 Inpatient care utilisation and expenditure associated with objective physical activity: econometric analysis of the UK Biobank
by Leonie Heron & Mark A. Tully & Frank Kee & Ciaran O’Neill - 499-512 Psychometric evaluation of the German version of the Recovering Quality of Life (ReQoL) measures in patients with affective disorders
by Thomas Grochtdreis & Hans-Helmut König & Anju Devianee Keetharuth & Jürgen Gallinat & Alexander Konnopka & Holger Schulz & Martin Lambert & Anne Karow & Judith Dams - 513-537 Lifetime direct healthcare costs of treating colorectal cancer: a systematic review
by Nazim Bhimani & Geoffrey YM Wong & Charles Molloy & Mbathio Dieng & Patrick J Kelly & Thomas J Hugh - 539-556 Sex differences in care complexity and cost of cardiac-related procedures as a basis for improving hospital payments systems
by Shuli Brammli-Greenberg & Sharvit Fialco & Neria Shtauber & Yoram Weiss - 557-574 Obesity and labour market outcomes in Italy: a dynamic panel data evidence with correlated random effects
by Antonio Pacifico - 575-590 Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations
by Karen Jordan & Christopher G. Fawsitt & Paul G. Carty & Barbara Clyne & Conor Teljeur & Patricia Harrington & Mairin Ryan - 591-607 The pass-through of excise taxes to market prices of heated tobacco products (HTPs) and cigarettes: a cross-country analysis
by Estelle Dauchy & Ce Shang - 609-619 Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands
by Paul Mark Mitchell & Rachael L. Morton & Mickaël Hiligsmann & Samantha Husbands & Joanna Coast - 621-632 Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients
by Elizabeth Parody-Rua & Alejandro Bustamante & Joan Montaner & Maria Rubio-Valera & David Serrano & Soledad Pérez-Sánchez & Alba Sánchez-Viñas & César Guevara-Cuellar & Antoni Serrano-Blanco - 633-646 A novel mathematical model for prioritization of individuals to receive vaccine considering governmental health protocols
by N. Shamsi Gamchi & M. Esmaeili - 647-659 Reducing the basic reproduction number of COVID-19: a model simulation focused on QALYs, hospitalisation, productivity costs and optimal (soft) lockdown
by Jose Robles-Zurita - 661-662 Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al
by Carlo Lazzaro - 663-672 Response letter for the comment made on our article entitled “Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease”, published online last May in the European Journal of Health Economics, doi: 10.1007/s10198-022-01471-9
by Juan Oliva-Moreno
April 2023, Volume 24, Issue 3
- 321-333 Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study
by Antoine Bessou & Xavier Colin & Julie De Nascimento & Will Sopwith & Shannon Ferrante & Boris Gorsh & Benjamin Gutierrez & Leah Sansbury & Jenny Willson & Sandhya Sapra & Prani Paka & Feng Wang - 335-347 Live and let live: understanding the temporal drivers and spillovers of life expectancy in Europe for public planning
by Pilar Gracia-de-Rentería & Hugo Ferrer-Pérez & Ana Isabel Sanjuán & George Philippidis - 349-358 Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation
by Bent Estler & Volker Rudolph & Yana Seleznova & Arim Shukri & Stephanie Stock & Dirk Müller - 359-376 Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis: systematic review of cost-effectiveness analysis
by Phatcharaphorn Chotnoppharatphatthara & Voratima Yoodee & Suthinee Taesotikul & Jirawit Yadee & Unchalee Permsuwan - 377-392 A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway
by Ellen Busink & Dana Kendzia & Fatih Kircelli & Sophie Boeger & Jovana Petrovic & Helen Smethurst & Stephen Mitchell & Christian Apel - 393-398 A hearing bolt-on item increased the measurement properties of the EQ-5D-5L in a community-based hearing loss screening program
by Pei Wang & Sheue-Lih Chong & Rachel Lee-Yin Tan & Nan Luo - 399-412 EQ-5D-5L: a value set for Romania
by Elena Olariu & Wael Mohammed & Yemi Oluboyede & Raluca Caplescu & Ileana Gabriela Niculescu-Aron & Marian Sorin Paveliu & Luke Vale - 413-423 Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention
by David J. Mott & Laura Ternent & Luke Vale - 425-436 Willingness to provide informal care to older adults in Germany: a discrete choice experiment
by Lea de Jong & Torben Schmidt & Jona Theodor Stahmeyer & Sveja Eberhard & Jan Zeidler & Kathrin Damm - 437-451 Does health technology assessment compromise access to pharmaceuticals?
by Melanie Büssgen & Tom Stargardt - 453-467 Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review
by Clare Proudfoot & Raju Gautam & Joaquim Cristino & Rumjhum Agrawal & Lalit Thakur & Keith Tolley - 469-478 Impact of a diabetes disease management program on guideline-adherent care, hospitalization risk and health care costs: a propensity score matching study using real-world data
by Marc Höglinger & Brigitte Wirth & Maria Carlander & Cornelia Caviglia & Christian Frei & Birgitta Rhomberg & Adrian Rohrbasser & Maria Trottmann & Klaus Eichler - 479-481 Making the rules make sense: valuation of constrained resources
by Jonathan Siverskog - 483-483 Reply to: making the rules make sense: valuation of constrained resources
by Peter Lindgren
March 2023, Volume 24, Issue 2
- 153-156 General practice in the EU: countries you see, customs you find
by Livio Garattini & Marco Badinella Martini & Alessandro Nobili - 157-168 Survival analysis of cancer patients in Portugal following the reference centre model implementation
by Manuel Melo Mateus & Margarida Catalão-Lopes & Rui Portugal - 169-177 Healthcare costs of diabetic foot disease in Italy: estimates for event and state costs
by Chiara Seghieri & Francesca Ferrè & Elisa Foresi & Alice Borghini - 179-186 Does a working day keep the doctor away? A critical review of the impact of unemployment and job insecurity on health and social care utilisation
by Keyi Li & Paula Lorgelly & Sarah Jasim & Tiyi Morris & Manuel Gomes - 187-196 Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China
by Phil McEwan & James Baker-Knight & Björg Ásbjörnsdóttir & Yunni Yi & Aimee Fox & Robin Wyn - 197-207 Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China
by Guizhi Weng & Yanming Hong & Nan Luo & Clara Mukuria & Jie Jiang & Zhihao Yang & Sha Li - 209-236 The association between bed occupancy rates and hospital quality in the English National Health Service
by Laia Bosque-Mercader & Luigi Siciliani - 237-246 Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost–utility analysis alongside a randomized HYPO-RT-PC trial
by Sun Sun & Håkan Jonsson & Klas-Göran Salén & Mats Andén & Lars Beckman & Per Fransson - 247-277 Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease
by B. Rodríguez-Sánchez & S. Daugbjerg & L. M. Peña-Longobardo & J. Oliva-Moreno & I. Aranda-Reneo & A. Cicchetti & J. López-Bastida - 279-292 Mapping the obesity problems scale to the SF-6D: results based on the Scandinavian Obesity Surgery Registry (SOReg)
by Sun Sun & Erik Stenberg & Yang Cao & Lars Lindholm & Klas-Göran Salén & Karl A. Franklin & Nan Luo - 293-305 Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology
by Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema - 307-319 Understanding bias in probabilistic analysis in model-based health economic evaluation
by Xuanqian Xie & Alexis K. Schaink & Sichen Liu & Myra Wang & Andrei Volodin
February 2023, Volume 24, Issue 1
- 1-4 Patient-reported measures: how useful in health economics?
by Anne-Gaëlle Corroller & Julia Bonastre - 5-25 On absolute socioeconomic health inequality comparisons
by Mohamad A. Khaled & Paul Makdissi & Myra Yazbeck - 27-38 Health state utilities for beta-thalassemia: a time trade-off study
by Antony P. Martin & Enrico Ferri Grazzi & Claudia Mighiu & Manoj Chevli & Farrukh Shah & Louise Maher & Anum Shaikh & Aliah Sagar & Hayley Hubberstey & Bethany Franks & Juan M. Ramos-Goñi & Mark Oppe & Derek Tang - 39-52 Vaccination or NPI? A conjoint analysis of German citizens' preferences in the context of the COVID-19 pandemic
by Jacques Bughin & Michele Cincera & Evelyn Kiepfer & Dorota Reykowska & Florian Philippi & Marcin Żyszkiewicz & Rafal Ohme & Dirk Frank - 53-66 Complexities of health and acceptance of electronic health records for the Austrian elderly population
by Nicole Halmdienst & Gerald J. Pruckner & Rudolf Winter-Ebmer - 67-74 The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies
by Florian Dorn & Sahamoddin Khailaie & Marc Stoeckli & Sebastian C. Binder & Tanmay Mitra & Berit Lange & Stefan Lautenbacher & Andreas Peichl & Patrizio Vanella & Timo Wollmershäuser & Clemens Fuest & Michael Meyer-Hermann - 75-80 Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis
by G. Fabiano & A. Marcellusi & F. S. Mennini & P. Sciattella & G. Favato - 81-98 Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment
by Jonathan Sicsic & Serge Blondel & Sandra Chyderiotis & François Langot & Judith E. Mueller - 99-110 Inequality, public health, and COVID-19: an analysis of the Spanish case by municipalities
by Ignacio Amate-Fortes & Almudena Guarnido-Rueda - 111-123 The goal of risk equalization in regulated competitive health insurance markets
by Wynand Ven & Gerrit Hamstra & Richard Kleef & Mieke Reuser & Piet Stam - 125-138 Financial risk allocation and provider incentives in hospital–insurer contracts in The Netherlands
by Chandeni S. Gajadien & Peter J. G. Dohmen & Frank Eijkenaar & Frederik T. Schut & Erik M. Raaij & Richard Heijink - 139-152 Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis
by Kamilla Koszorú & Krisztina Hajdu & Valentin Brodszky & Alex Bató & L. Hunor Gergely & Anikó Kovács & Zsuzsanna Beretzky & Miklós Sárdy & Andrea Szegedi & Fanni Rencz
December 2022, Volume 23, Issue 9
- 1415-1436 Reassessing the impact of health expenditure on income growth in the face of the global sanitary crisis: the case of developing countries
by Brahim Gaies - 1437-1453 Should administrative costs in health insurance be included in the risk-equalization? An analysis of five countries
by Rudy Douven & Lukas Kauer & Sylvia Demme & Francesco Paolucci & Wynand Ven & Jürgen Wasem & Xiaoxi Zhao - 1455-1482 Determinants of willingness to pay for health services: a systematic review of contingent valuation studies
by Caroline Steigenberger & Magdalena Flatscher-Thoeni & Uwe Siebert & Andrea M. Leiter - 1483-1496 Population preferences for non-pharmaceutical interventions to control the SARS-CoV-2 pandemic: trade-offs among public health, individual rights, and economics
by Axel C. Mühlbacher & Andrew Sadler & Yvonne Jordan - 1497-1518 Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs’ reimbursements
by Eduardo Costa & Carolina Santos - 1519-1533 Equity in healthcare utilization in Canada’s publicly funded health system: 2000–2014
by Laura Hirello & Mohammad Habibullah Pulok & Mohammad Hajizadeh - 1535-1545 The effect of informal caregiving on medication: evidence from administrative data
by Magdalena Stroka-Wetsch - 1547-1562 The attractiveness of jobs in the German care sector: results of a factorial survey
by Martin Kroczek & Jochen Späth - 1563-1575 Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database
by Zuzana Špacírová & David Epstein & Jaime Espín - 1577-1590 A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots
by Elahe Khorasani & Majid Davari & Abbas Kebriaeezadeh & Farshad Fatemi & Ali Akbari Sari & Vida Varahrami - 1591-1599 The impact of cost-sharing on prescription drug demand: evidence from a double-difference regression kink design
by Simona Gamba & Niklas Jakobsson & Mikael Svensson - 1601-1612 Looking into the black box of “Medical Innovation”: rising health expenditures by illness type
by Friedrich Breyer & Normann Lorenz & Gerald J. Pruckner & Thomas Schober - 1613-1615 Correction to: Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology
by Stefan A. Lipman & Liying Zhang & Koonal K. Shah & Arthur E. Attema
November 2022, Volume 23, Issue 8
- 1259-1261 Breaking the rules: decision-making under absolute resource constraints
by Peter Lindgren - 1263-1285 COVID-19 health policy evaluation: integrating health and economic perspectives with a data envelopment analysis approach
by Matthias Klumpp & Dominic Loske & Silvio Bicciato - 1287-1296 Value drivers of development stage biopharma companies
by Daniel Tobias Michaeli & Hasan Basri Yagmur & Timur Achmadeev & Thomas Michaeli - 1297-1308 Do we care about high-cost patients? Estimating the savings on health spending by integrated care
by Karen Geurts & Marc Bruijnzeels & Erik Schokkaert - 1309-1317 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska - 1319-1328 Does the abolition of copayment increase ambulatory care utilization?: a quasi-experimental study in Germany
by Mingming Xu & Benjamin Bittschi - 1329-1340 The impact of ambulatory care spending, continuity and processes of care on ambulatory care sensitive hospitalizations
by Wiebke Schuettig & Leonie Sundmacher - 1341-1355 Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above
by Zsombor Zrubka & Péter Vékás & Péter Németh & Ágota Dobos & Ottó Hajdu & Levente Kovács & László Gulácsi & Judith Hibbard & Márta Péntek - 1357-1369 Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data
by Aileen R. Neilson & Gareth T. Jones & Gary J. Macfarlane & Ejaz MI Pathan & Paul McNamee - 1371-1381 Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective
by Daniela Zinzi & Ioanna Vlachaki & Edel Falla & Theo Mantopoulos & Dilip Nathwani - 1383-1395 Psychometric performance of proxy-reported EQ-5D youth version 5-level (EQ-5D-Y-5L) in comparison with three-level (EQ-5D-Y-3L) in children and adolescents with scoliosis
by Jiaer Lin & Carlos King Ho Wong & Jason Pui Yin Cheung & Prudence Wing Hang Cheung & Nan Luo - 1397-1411 Does voluntary health insurance improve health and longevity? Evidence from European OECD countries
by Simona Laura Dragos & Codruta Mare & Cristian Mihai Dragos & Gabriela Mihaela Muresan & Alexandra-Anca Purcel - 1413-1413 Correction: Lifetime direct healthcare costs of treating colorectal cancer: a systematic review
by Nazim Bhimani & Geoffrey Y. M. Wong & Charles Molloy & Mbathio Dieng & Patrick J. Kelly & Thomas J. Hugh
September 2022, Volume 23, Issue 7
- 1079-1083 Challenges for health systems seeking to embrace virtual health care for population health
by Panos Kanavos & Michelle Vogelsang & Madeleine Haig & Vasiliki Kolovou - 1085-1104 Defining minimum volume thresholds to increase quality of care: a new patient-oriented approach using mixed integer programming
by Justus F. A. Vogel & Max Barkhausen & Christoph M. Pross & Alexander Geissler - 1105-1119 Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia
by Abraham G. Welie & Elly Stolk & Clara Mukuria & Yared Belete Belay & Murray D. Krahn & Beate Sander & Gebremedhin Beedemariam Gebretekle - 1121-1149 Ageing and health care expenditures: the importance of age per se, steepening of the individual-level expenditure curve, and the role of morbidity
by Anna Kollerup & Jakob Kjellberg & Rikke Ibsen - 1151-1157 Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economists
by Paolo Candio & Koen B. Pouwels & David Meads & Andrew J. Hill & Laura Bojke & Claire Williams - 1159-1171 Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
by Hidetoshi Shibahara & Takeru Shiroiwa & Megumi Ishiguro & Masato Nakamura & Junichi Hasegawa & Shigeki Yamaguchi & Yuriko Masuda & Junichi Sakamoto & Naohiro Tomita & Takashi Fukuda - 1173-1185 Probabilistic microsimulation to examine the cost-effectiveness of hospital admission screening strategies for carbapenemase-producing enterobacteriaceae (CPE) in the United Kingdom
by Sarkis Manoukian & Sally Stewart & Stephanie J. Dancer & Helen Mason & Nicholas Graves & Chris Robertson & Alistair Leonard & Sharon Kennedy & Kim Kavanagh & Benjamin Parcell & Jacqui Reilly - 1187-1201 Catastrophic household expenditure associated with out-of-pocket payments for dental healthcare in Spain
by Samuel López-López & Raúl Pozo-Rubio & Marta Ortega-Ortega & Francisco Escribano-Sotos - 1203-1220 Supply-side solutions targeting demand-side characteristics: causal effects of a chronic disease management program on adherence and health outcomes
by Luke Connelly & Gianluca Fiorentini & Marica Iommi - 1221-1227 Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups
by Mohamed N. M. T. Al Khayat & Job F. H. Eijsink & Maarten J. Postma & Ewoudt M. W. Garde & Marinus Hulst - 1229-1242 Can competition improve hospital quality of care? A difference-in-differences approach to evaluate the effect of increasing quality transparency on hospital quality
by Christoph Strumann & Alexander Geissler & Reinhard Busse & Christoph Pross - 1243-1255 Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology
by Zoltán Hermann & Márta Péntek & László Gulácsi & Irén Anna Kopcsóné Németh & Zsombor Zrubka - 1257-1257 Correction to: Geographic distribution of physicians in Portugal
by Isabel Correia & Paula Veiga
August 2022, Volume 23, Issue 6
- 913-915 European union regulation of health technology assessment: what is required for it to succeed?
by Michael Drummond & Rosanna Tarricone & Aleksandra Torbica - 917-940 Comparison of ARIMA, ETS, NNAR, TBATS and hybrid models to forecast the second wave of COVID-19 hospitalizations in Italy
by Gaetano Perone - 941-952 Resource utilization and disaggregated cost analysis of bariatric surgery in the Australian public healthcare system
by Qing Xia & Julie A. Campbell & Hasnat Ahmad & Barbara Graaff & Lei Si & Petr Otahal & Kevin Ratcliffe & Julie Turtle & John Marrone & Mohammed Huque & Barry Hagan & Matthew Green & Andrew J. Palmer - 953-968 Does compulsory schooling affect health? Evidence from ambulatory claims data
by Tatjana Begerow & Hendrik Jürges - 969-978 Optimising the impact of COVID-19 vaccination on mortality and hospitalisations using an individual additive risk measuring approach based on a risk adjustment scheme
by Danny Wende & Dagmar Hertle & Claudia Schulte & Pedro Ballesteros & Uwe Repschläger - 979-991 Costing methodologies in European economic evaluation guidelines: commonalities and divergences
by Leticia García-Mochón & Zuzana Špacírová & Jaime Espín - 993-1005 The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria: a time trade-off and discrete choice experiment study
by Sara Olofsson & Katarina Gralén & Christina Hoxer & Paul Okhuoya & Ulf Persson - 1007-1014 The remarkably frequent use of EQ-5D in non-economic research
by Aimin Wang & Kim Rand & Zhihao Yang & Richard Brooks & Jan Busschbach - 1015-1035 Income level and antibiotic misuse: a systematic review and dose–response meta-analysis
by Narmeen Mallah & Nicola Orsini & Adolfo Figueiras & Bahi Takkouche - 1037-1057 Willingness-to-pay for cancer treatment and outcome: a systematic review
by Alene Sze Jing Yong & Yi Heng Lim & Mark Wing Loong Cheong & Ednin Hamzah & Siew Li Teoh - 1059-1070 Value appropriation in hepatitis C
by Peter Lindgren & Sofia Löfvendahl & Gunnar Brådvik & Ola Weiland & Bengt Jönsson - 1071-1078 Decision thresholds with genetic testing
by Stefan Felder
July 2022, Volume 23, Issue 5
- 759-761 Seeking efficiency gains outside drugs and diagnostics
by Reyes Lorente & Fernando Antonanzas - 763-779 The cost-effectiveness of unilateral cochlear implants in UK adults
by Henry Cutler & Mutsa Gumbie & Emma Olin & Bonny Parkinson & Ross Bowman & Hafsa Quadri & Timothy Mann - 781-789 What drives variations in public health and social services expenditures? the association between political fragmentation and local expenditure patterns
by Yonsu Kim & Jae Hong Kim - 791-805 Adoption of large-scale medical equipment: the impact of competition in the German inpatient sector
by Marie Dreger & Hauke Langhoff & Cornelia Henschke - 807-821 Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland
by Claudine Bommer & Judith Lupatsch & Nicole Bürki & Matthias Schwenkglenks - 823-835 Characteristics and health care costs in patients with a diagnostic imaging for low back pain in Switzerland
by Stefania Di Gangi & Christophe Bagnoud & Giuseppe Pichierri & Thomas Rosemann & Andreas Plate - 837-846 Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
by Michaela Barbier & Nicholas Durno & Craig Bennison & Mathias Örtli & Christian Knapp & Matthias Schwenkglenks - 847-861 The effects of patient cost-sharing on health expenditure and health among older people: Heterogeneity across income groups
by Hirotaka Kato & Rei Goto & Taishi Tsuji & Katsunori Kondo - 863-878 Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
by Agnes Kisser & Joschua Knieriemen & Annette Fasan & Karolin Eberle & Sara Hogger & Sebastian Werner & Tina Taube & Andrej Rasch - 879-891 One last effort. Are high out-of-pocket payments at the end of life a fatality?
by Rosalind Bell-Aldeghi & Nicolas Sirven & Morgane Guern & Christine Sevilla-Dedieu - 893-901 Work ethics, stay-at-home measures and COVID-19 diffusion
by Vincenzo Alfano - 903-912 Examining the density in out-of-pocket spending share in the estimation of catastrophic health expenditures
by Abdulrahman Jbaily & Annie Haakenstad & Mizan Kiros & Carlos Riumallo-Herl & Stéphane Verguet
June 2022, Volume 23, Issue 4
- 559-563 Microeconomics of intertemporal choice in zero-space during Covid-19: a behavioral economics perspective
by Javier Cifuentes-Faura & Renaud Francesco - 565-595 Short- and medium-term cost effects of non-indicated thyroid diagnostics: empirical evidence from German claims data
by Lucas Hafner & Valeria Biermann & Susann Hueber & Ewan Donnachie & Thomas Kühlein & Harald Tauchmann & Johanna Tomandl - 597-606 A dynamic Markov model to assess the cost-effectiveness of the Kidney Team at Home intervention in The Netherlands
by Steef Redeker & Sohal Ismail & Hester V. Eeren & Emma K. Massey & Willem Weimar & Mark Oppe & Jan Busschbach - 607-615 Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life
by Dan Cai & Si Shi & Shan Jiang & Lei Si & Jing Wu & Yawen Jiang - 617-625 Communities and testing for COVID-19
by Steven Stillman & Mirco Tonin - 627-643 Infections, accidents and nursing overtime in a neonatal intensive care unit
by Marc Beltempo & Georges Bresson & Jean-Michel Étienne & Guy Lacroix - 645-669 Consideration of quality of life in the health technology assessments of rare disease treatments
by Elena Nicod & Michela Meregaglia & Amanda Whittal & Sheela Upadhyaya & Karen Facey & Michael Drummond - 671-685 The residential healthcare for the elderly in Italy: some considerations for post-COVID-19 policies
by Alessandra Cepparulo & Luisa Giuriato - 687-703 Is stronger religious faith associated with a greater willingness to take the COVID-19 vaccine? Evidence from Israel and Japan
by Eyal Lahav & Shosh Shahrabani & Mosi Rosenboim & Yoshiro Tsutsui - 705-715 The impact of decentralisation on the performance of health care systems: a non-linear relationship
by Sean Dougherty & Luca Lorenzoni & Alberto Marino & Fabrice Murtin - 717-728 Using Australian panel data to account for unobserved factors in measuring inequities for different channels of healthcare utilization
by Jonas Fooken & Varinder Jeet - 729-753 The COVID-19 crisis and telework: a research survey on experiences, expectations and hopes
by Eline Moens & Louis Lippens & Philippe Sterkens & Johannes Weytjens & Stijn Baert - 755-756 Demonstrating the value of cancer biomarkers at the population level
by Afschin Gandjour - 757-758 Reply to comment on “Demonstrating the value of cancer biomarkers at the population”
by Ana Beatriz D’Avó Luís & Mikyung Kelly Seo
April 2022, Volume 23, Issue 3
- 329-335 Public health policies for the common interest: rethinking EU states’ incentives strategies when a pandemic reshuffles all interests
by Juan Llano & Jorge Mestre-Ferrandiz & Jaime Espin & Jordi Gol-Montserrat & Alicia Llano & Carlos Bringas - 337-356 Online and offline health information seeking and the demand for physician services
by Hiroaki Suenaga & Maria Rosalía Vicente - 357-374 Valuing informal carers’ quality of life using best-worst scaling—Finnish preference weights for the Adult Social Care Outcomes Toolkit for carers (ASCOT-Carer)
by Lien Nguyen & Hanna Jokimäki & Ismo Linnosmaa & Eirini-Christina Saloniki & Laurie Batchelder & Juliette Malley & Hui Lu & Peter Burge & Birgit Trukeschitz & Julien Forder - 375-431 Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability
by Suaad Almajed & Nora Alotaibi & Sana Zulfiqar & Zahraa Dhuhaibawi & Niall O’Rourke & Richard Gaule & Caoimhe Byrne & Aaron M. Barry & Dylan Keeley & James F. O’Mahony - 433-451 A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE)
by Darius N. Lakdawalla & Charles E. Phelps - 453-465 Does the amount of formal care affect informal care? Evidence among over-60s in France
by Elsa Perdrix & Quitterie Roquebert